



GRACEcast

Direct From ASCO 2015:
Highlights & New Approaches in Kidney Cancer

Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?



Toni Choueiri, MD
Clinical Dir., Lank Center for Genitourinary Oncology &
Director, Kidney Cancer Center
Dana-Farber Cancer Institute
Assoc. Professor of Medicine, Harvard Medical School



Sumanta (Monty) Pal, MD
Asst. Professor, Dept. of Medical Oncology &
Therapeutics Research
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center

GRACEcast

Direct From ASCO 2015:

Highlights & New Approaches in Kidney Cancer

Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?

TRANSCRIPT

Dr. Pal: Well, it's a great honor to be here today with Dr. Toni Choueiri, from the Dana-Farber Cancer Institute. I consider him to be a real legend in the field of renal cell carcinoma, so it's great to get his perspectives on the disease. So, Toni, just to begin, we're talking about nivolumab, now perhaps more in the context of second or third-line therapy. What is the status of PD-1 inhibitors in the front-line setting; what are some trials you're excited about that are ongoing right now?

Dr. Choueiri: So, one of the interesting trials combined two immune checkpoint blockers, which does make sense – we don't have any evidence that they're both redundant, and perhaps both at the same time are better than one alone, or than what we have available. So that is an ongoing large trial of combining nivolumab, which is a PD-1 inhibitor, with ipilimumab, which is a CTLA-4 blocker, compared to a standard therapy, which is sunitinib first-line – that's a very exciting trial.

Another trial compares a PD-L1 inhibitor, plus a VEGF inhibitor, bevacizumab – so a different mechanism of action, versus front-line standard sunitinib.

These are all kind of exciting, you're going to see data in the plenary session about nivolumab plus ipilimumab – a large trial in melanoma seems to have higher response rates. So, you know, we're monitoring this field by the day and it may change, whether in renal cell carcinoma or other tumors. So, I believe immune checkpoint blockers, especially PD-1 inhibitors, are here to stay. They are, in fact, approved now in several indications, and we are going to see soon, whether the results – what the results are in renal cell cancer in that tumor setting.

Dr. Pal: Great, well, Toni, as always I learned a lot from chatting with you, and thank you so much for your time.

Dr. Choueiri: Absolutely, thank you Monty.

Presented by



Global
Resource for
Advancing
Cancer
Education

cancerGRACE.org

Check out the **GRACE** website
for additional videos
and other educational content

GRACE.expert/ASCO2015Kidney